Sign in or create an account to add this stock to your watchlist.
About Advanced Oncotherapy (LON:AVO)
Advanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. It is involved in developing Linac Image Guided Hadron technology, a proton therapy system for treating cancer. The company is also involved in the management of a healthcare related property. It operates in the United Kingdom, Switzerland, and the Unites States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy PLC was incorporated in 2005 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
SymbolLON:AVO
CUSIPN/A
Phone+44-20-36178728
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-43.18%
Return on Assets-35.03%
Miscellaneous
EmployeesN/A
Outstanding Shares80,940,000
Advanced Oncotherapy (LON:AVO) Frequently Asked Questions
What is Advanced Oncotherapy's stock symbol?
Advanced Oncotherapy trades on the London Stock Exchange (LON) under the ticker symbol "AVO."
Who are some of Advanced Oncotherapy's key competitors?
Some companies that are related to Advanced Oncotherapy include Hamilton Thorne (HTL), Kromek Group (KMK), Electromed (ELMD), Universal Biosensors (UBI), Patient Home Monitoring (PHM), MRI Interventions (MRIC), Surgical Innovations (SUN), NeuroOne Medical Tech (NMTC), PetVivo (PETV), Avacta Group (AVCT), Myomo (MYO), Airware Labs (AIRW), Inspiration Healthcare Group (IHC), HCi VioCare (VICA) and Arrhythmia Research Technology (MICR).
Who are Advanced Oncotherapy's key executives?
Advanced Oncotherapy's management team includes the folowing people:
- Dr. Michael Jeffrey Sinclair, Exec. Chairman (Age 75)
- Mr. Nicolas Serandour, CEO & Exec. Director
- Dr. Sanjeev Pandya, Exec. VP for Global Bus. Devel. and Exec. Director
- Mr. Ed Lee, COO & Sr. VP of Operations
- Mr. Graham Pughe, Sr. VP of Accounting & IT
Has Advanced Oncotherapy been receiving favorable news coverage?
Press coverage about AVO stock has been trending somewhat positive on Monday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Advanced Oncotherapy earned a coverage optimism score of 0.05 on Accern's scale. They also gave news coverage about the company an impact score of 47.47 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Advanced Oncotherapy?
Shares of AVO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Advanced Oncotherapy's stock price today?
One share of AVO stock can currently be purchased for approximately GBX 52.57.
How big of a company is Advanced Oncotherapy?
Advanced Oncotherapy has a market capitalization of £41.31 million.
How can I contact Advanced Oncotherapy?
Advanced Oncotherapy's mailing address is Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom. The company can be reached via phone at +44-20-36178728.
MarketBeat Community Rating for Advanced Oncotherapy (AVO)
MarketBeat's community ratings are surveys of what our community members think about Advanced Oncotherapy and other stocks. Vote "Outperform" if you believe AVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Advanced Oncotherapy (LON:AVO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | N/A | Hold | Hold |
| Consensus Rating Score: | N/A | N/A | 2.00 | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
Advanced Oncotherapy (LON:AVO) Consensus Price Target History
Advanced Oncotherapy (LON:AVO) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Advanced Oncotherapy (LON:AVO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Advanced Oncotherapy (LON AVO) Insider Trading and Institutional Ownership History
Advanced Oncotherapy (LON AVO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/11/2018 | Enrico Cipro Vanni | Insider | Buy | 40,000 | GBX 55 | £22,000 | | |
| 7/31/2017 | Enrico Cipro Vanni | Insider | Buy | 100,000 | GBX 18 | £18,000 | | |
| 5/15/2017 | Steve Myers OBE | Insider | Buy | 400,000 | GBX 26 | £104,000 | | |
| 5/9/2017 | Christopher Nutting | Insider | Buy | 202,500 | GBX 25 | £50,625 | | |
| 4/25/2017 | Michael J Sinclair | Insider | Buy | 200,000 | GBX 30 | £60,000 | | |
| 4/24/2017 | Enrico Cipro Vanni | Insider | Buy | 100,000 | GBX 27 | £27,000 | | |
| 4/12/2017 | Enrico Cipro Vanni | Insider | Buy | 100,000 | GBX 28 | £28,000 | | |
| 4/4/2017 | Enrico Cipro Vanni | Insider | Buy | 25,000 | GBX 29 | £7,250 | | |
| 4/3/2017 | Michael J Sinclair | Insider | Buy | 100,000 | GBX 28 | £28,000 | | |
| 1/3/2017 | Enrico Cipro Vanni | Insider | Buy | 25,000 | GBX 87 | £21,750 | | |
| 12/29/2016 | Enrico Cipro Vanni | Insider | Buy | 25,000 | GBX 66 | £16,500 | | |
| 12/22/2016 | Enrico Cipro Vanni | Insider | Buy | 25,000 | GBX 60 | £15,000 | | |
| 12/20/2016 | Enrico Cipro Vanni | Insider | Buy | 25,000 | GBX 55 | £13,750 | | |
| 12/19/2016 | Enrico Cipro Vanni | Insider | Buy | 25,000 | GBX 50 | £12,500 | | |
| 7/11/2016 | Bradfield ,Michael | Insider | Buy | 30,000 | GBX 135 | £40,500 | | |
| 7/8/2016 | Bradfield ,Michael | Insider | Buy | 10,000 | GBX 120 | £12,000 | | |
| 7/7/2016 | Bradfield ,Michael | Insider | Buy | 10,000 | GBX 112 | £11,200 | | |
| 7/6/2016 | Bradfield ,Michael | Insider | Buy | 50,000 | GBX 102 | £51,000 | | |
| 12/18/2015 | Bradfield ,Michael | Insider | Buy | 750,000 | GBX 7 | £52,500 | | |
| 12/17/2015 | Bradfield ,Michael | Insider | Buy | 1,000,000 | GBX 6 | £60,000 | | |
| 12/16/2015 | Bradfield ,Michael | Insider | Buy | 750,000 | GBX 6 | £45,000 | | |
| 7/20/2015 | Vanni ,Enrico Cipro | Insider | Buy | 1,000,000 | GBX 8 | £80,000 | | |
| 7/1/2015 | Sinclair,Michael J | Insider | Sell | 7,000,000 | GBX 0.08 | £5,600 | | |
| 6/5/2015 | Michael Bradfield | Insider | Buy | 1,500,000 | GBX 9.81 | £147,150 | | |
| 2/4/2015 | Michael Bradfield | Insider | Buy | 500,000 | GBX 4.10 | £20,500 | | |
(Data available from 1/1/2013 forward)
Advanced Oncotherapy (LON AVO) News Headlines
| Source: |
|
Advanced Oncotherapy (LON:AVO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Advanced Oncotherapy (LON AVO) Stock Chart for Monday, May, 21, 2018
Loading chart…
